Home/Pipeline/Everolimus (Afinitor®)

Everolimus (Afinitor®)

Oncology

ANDA ApprovedLaunched Q1 2025

Key Facts

Indication

Oncology

Phase

ANDA Approved

Status

Launched Q1 2025

Company

Amneal Pharmaceuticals

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, founded in 2002 and publicly traded (NYSE: AMRX), has evolved from a generic drug company into a diversified biopharmaceutical enterprise with a mission to make medicine accessible for all. Its strategy is built on a three-pillar portfolio of complex generics, biosimilars, and specialty injectables, supported by significant U.S. manufacturing reinvestment. Recent high-profile launches like Brekiya for migraine and CREXONT for Parkinson's disease demonstrate its capability to develop and commercialize advanced, difficult-to-formulate products that address unmet patient needs and generate sustainable growth.

View full company profile

Therapeutic Areas

Oncology Central Nervous System Gastroenterology Emergency/Critical Care Hematology Ophthalmology Psychiatry

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active